These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
5. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. Gallego-Colon E; Daum A; Yosefy C Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335 [TBL] [Abstract][Full Text] [Related]
7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye? Boffa MB; Koschinsky ML Curr Opin Lipidol; 2019 Dec; 30(6):428-437. PubMed ID: 31577611 [TBL] [Abstract][Full Text] [Related]
9. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis. Lu X Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742 [TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events. Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008 [TBL] [Abstract][Full Text] [Related]
11. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. Oleaga C; Shapiro MD; Hay J; Mueller PA; Miles J; Huang C; Friz E; Tavori H; Toth PP; Wójcik C; Warden BA; Purnell JQ; Duell PB; Pamir N; Fazio S J Am Coll Cardiol; 2021 Oct; 78(14):1437-1449. PubMed ID: 34593126 [TBL] [Abstract][Full Text] [Related]
13. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults. Davis LE; Pogge EK High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891 [TBL] [Abstract][Full Text] [Related]
14. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. Turgeon RD; Pearson GJ Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110 [TBL] [Abstract][Full Text] [Related]
16. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Krittanawong C; Khawaja M; Rosenson RS; Amos CI; Nambi V; Lavie CJ; Virani SS Curr Probl Cardiol; 2022 Jul; 47(7):101043. PubMed ID: 34780866 [TBL] [Abstract][Full Text] [Related]
17. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281 [TBL] [Abstract][Full Text] [Related]
18. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
19. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686 [TBL] [Abstract][Full Text] [Related]